Outset Medical Analyst Ratings
Outset Medical Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/14/2023 | 19.05% | Morgan Stanley | $19 → $5 | Maintains | Equal-Weight |
10/13/2023 | 304.76% | RBC Capital | $29 → $17 | Maintains | Outperform |
10/13/2023 | 42.86% | Stifel | $26 → $6 | Maintains | Buy |
10/13/2023 | -28.57% | B of A Securities | $32 → $3 | Downgrades | Buy → Underperform |
08/24/2023 | 352.38% | Morgan Stanley | $22 → $19 | Maintains | Equal-Weight |
08/17/2023 | 590.48% | RBC Capital | → $29 | Reiterates | Outperform → Outperform |
08/17/2023 | — | CL King | Initiates Coverage On | → Neutral | |
08/03/2023 | 423.81% | Morgan Stanley | $23 → $22 | Maintains | Equal-Weight |
05/31/2023 | 447.62% | Morgan Stanley | $27 → $23 | Maintains | Equal-Weight |
05/15/2023 | 590.48% | RBC Capital | → $29 | Reiterates | Outperform → Outperform |
05/04/2023 | 590.48% | RBC Capital | $32 → $29 | Maintains | Outperform |
01/06/2023 | 542.86% | Morgan Stanley | $17 → $27 | Maintains | Equal-Weight |
11/11/2022 | 447.62% | RBC Capital | → $23 | Initiates Coverage On | → Outperform |
11/10/2022 | 304.76% | Morgan Stanley | $19 → $17 | Maintains | Equal-Weight |
11/09/2022 | 590.48% | Goldman Sachs | $34 → $29 | Maintains | Buy |
10/11/2022 | 352.38% | Morgan Stanley | $22 → $19 | Maintains | Equal-Weight |
08/03/2022 | 709.52% | Goldman Sachs | $48 → $34 | Maintains | Buy |
08/02/2022 | 423.81% | Morgan Stanley | $20 → $22 | Maintains | Equal-Weight |
07/18/2022 | 471.43% | Stifel | $30 → $24 | Maintains | Buy |
07/14/2022 | 376.19% | Morgan Stanley | $48 → $20 | Downgrades | Overweight → Equal-Weight |
06/14/2022 | 685.71% | Cowen & Co. | $60 → $33 | Maintains | Outperform |
06/14/2022 | 614.29% | Stifel | $55 → $30 | Maintains | Buy |
05/05/2022 | 1042.86% | Morgan Stanley | $50 → $48 | Maintains | Overweight |
05/05/2022 | 1209.52% | SVB Leerink | $65 → $55 | Maintains | Outperform |
08/18/2021 | 1566.67% | Cowen & Co. | → $70 | Initiates Coverage On | → Outperform |
08/09/2021 | 1209.52% | Morgan Stanley | $60 → $55 | Maintains | Equal-Weight |
05/06/2021 | 1328.57% | Morgan Stanley | $58 → $60 | Maintains | Equal-Weight |
04/19/2021 | 1400% | Wells Fargo | → $63 | Initiates Coverage On | → Overweight |
03/10/2021 | 1280.95% | Morgan Stanley | $52 → $58 | Maintains | Equal-Weight |
12/16/2020 | — | Oppenheimer | Initiates Coverage On | → Perform | |
12/15/2020 | 1138.1% | Morgan Stanley | $48 → $52 | Maintains | Equal-Weight |
10/12/2020 | 1328.57% | SVB Leerink | → $60 | Initiates Coverage On | → Outperform |
10/12/2020 | 1185.71% | Stifel | → $54 | Initiates Coverage On | → Buy |
10/12/2020 | 1042.86% | Morgan Stanley | → $48 | Initiates Coverage On | → Equal-Weight |
日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
---|---|---|---|---|---|
11/14/2023 | 19.05% | 摩根士丹利 | 19 美元 → 5 美元 | 維護 | 重量相等 |
10/13/2023 | 304.76% | 加拿大皇家銀行資本 | 29 美元 → 17 美元 | 維護 | 跑贏大盤 |
10/13/2023 | 42.86% | Stifel | 26 美元 → 6 美元 | 維護 | 買 |
10/13/2023 | -28.57% | B of A 類證券 | 32 美元 → 3 美元 | 降級 | 買入 → 表現不佳 |
08/24/2023 | 352.38% | 摩根士丹利 | 22 美元 → 19 美元 | 維護 | 重量相等 |
08/17/2023 | 590.48% | 加拿大皇家銀行資本 | → 29 美元 | 重申 | 跑贏大盤 → 跑贏大盤 |
08/17/2023 | — | CL King | 啓動覆蓋範圍開啓 | → 中立 | |
08/03/2023 | 423.81% | 摩根士丹利 | 23 美元 → 22 美元 | 維護 | 重量相等 |
05/31/2023 | 447.62% | 摩根士丹利 | 27 美元 → 23 美元 | 維護 | 重量相等 |
05/15/2023 | 590.48% | 加拿大皇家銀行資本 | → 29 美元 | 重申 | 跑贏大盤 → 跑贏大盤 |
05/04/2023 | 590.48% | 加拿大皇家銀行資本 | 32 美元 → 29 美元 | 維護 | 跑贏大盤 |
01/06/2023 | 542.86% | 摩根士丹利 | 17 美元 → 27 美元 | 維護 | 重量相等 |
11/11/2022 | 447.62% | 加拿大皇家銀行資本 | → 23 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
2022 年 10 月 11 日 | 304.76% | 摩根士丹利 | 19 美元 → 17 美元 | 維護 | 重量相等 |
11/09/2022 | 590.48% | 高盛 | 34 美元 → 29 美元 | 維護 | 買 |
2022 年 10 月 11 日 | 352.38% | 摩根士丹利 | 22 美元 → 19 美元 | 維護 | 重量相等 |
08/03/2022 | 709.52% | 高盛 | 48 美元 → 34 美元 | 維護 | 買 |
08/02/2022 | 423.81% | 摩根士丹利 | 20 美元 → 22 美元 | 維護 | 重量相等 |
07/18/2022 | 471.43% | Stifel | 30 美元 → 24 美元 | 維護 | 買 |
07/14/2022 | 376.19% | 摩根士丹利 | 48 美元 → 20 美元 | 降級 | 超重 → 重量相等 |
06/14/2022 | 685.71% | Cowen & Co. | 60 美元 → 33 美元 | 維護 | 跑贏大盤 |
06/14/2022 | 614.29% | Stifel | 55 美元 → 30 美元 | 維護 | 買 |
05/05/2022 | 1042.86% | 摩根士丹利 | 50 美元 → 48 美元 | 維護 | 超重 |
05/05/2022 | 1209.52% | SVB Leerink | 65 美元 → 55 美元 | 維護 | 跑贏大盤 |
2021 年 8 月 18 日 | 1566.67% | Cowen & Co. | → 70 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
2021 年 9 月 8 日 | 1209.52% | 摩根士丹利 | 60 美元 → 55 美元 | 維護 | 重量相等 |
05/06/2021 | 1328.57% | 摩根士丹利 | 58 美元 → 60 美元 | 維護 | 重量相等 |
2021 年 4 月 19 日 | 1400% | 富國銀行 | → 63 美元 | 啓動覆蓋範圍開啓 | → 超重 |
03/10/2021 | 1280.95% | 摩根士丹利 | 52 美元 → 58 美元 | 維護 | 重量相等 |
2020 年 12 月 16 日 | — | 奧本海默 | 啓動覆蓋範圍開啓 | → 表演 | |
2020 年 12 月 15 日 | 1138.1% | 摩根士丹利 | 48 美元 → 52 美元 | 維護 | 重量相等 |
10/12/2020 | 1328.57% | SVB Leerink | → 60 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
10/12/2020 | 1185.71% | Stifel | → 54 美元 | 啓動覆蓋範圍開啓 | → 購買 |
10/12/2020 | 1042.86% | 摩根士丹利 | → 48 美元 | 啓動覆蓋範圍開啓 | → 重量相等 |
What is the target price for Outset Medical (OM)?
Extinal Medical(OM)的目標價格是多少?
The latest price target for Outset Medical (NASDAQ: OM) was reported by Morgan Stanley on November 14, 2023. The analyst firm set a price target for $5.00 expecting OM to rise to within 12 months (a possible 19.05% upside). 12 analyst firms have reported ratings in the last year.
摩根士丹利於2023年11月14日公佈了Ontart Medical(納斯達克股票代碼:OM)的最新目標股價。該分析公司將目標股價定爲5.00美元,預計OM將在12個月內升至12個月內(可能上漲19.05%)。去年有12家分析公司公佈了評級。
What is the most recent analyst rating for Outset Medical (OM)?
Extinant Medical(OM)的最新分析師評級是多少?
The latest analyst rating for Outset Medical (NASDAQ: OM) was provided by Morgan Stanley, and Outset Medical maintained their equal-weight rating.
摩根士丹利對Outted Medical(納斯達克股票代碼:OM)的最新分析師評級由摩根士丹利提供,Ontart Medical維持同等權重評級。
When is the next analyst rating going to be posted or updated for Outset Medical (OM)?
Extinal Medical(OM)的下一次分析師評級何時發佈或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Outset Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Outset Medical was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
分析師在進行了廣泛的研究後得出了股票評級,其中包括瀏覽公開財務報表,與Outtar Medical的高管和客戶交談,以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級,因此每家公司每年應該獲得4次評級。Outpart Medical的最新評級是在2023年11月14日發佈的,因此您應該預計下一個評級將在2024年11月14日左右公佈。
Is the Analyst Rating Outset Medical (OM) correct?
分析師評級 Entinsion Medical (OM) 是否正確?
While ratings are subjective and will change, the latest Outset Medical (OM) rating was a maintained with a price target of $19.00 to $5.00. The current price Outset Medical (OM) is trading at is $4.20, which is out of the analyst's predicted range.
儘管評級是主觀的,並且會發生變化,但最新的Outtar Medical(OM)評級保持不變,目標股價爲19.00美元至5.00美元。Outtart Medical(OM)目前的交易價格爲4.20美元,超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。